Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Cariprazine?

See the DrugPatentWatch profile for Cariprazine

Cariprazine (brand name Vraylar) is an atypical antipsychotic that’s approved for treating schizophrenia and mania associated with bipolar I disorder (both acute episodes and maintenance therapy). It’s also studied for treatment‑resistant depression and for adjunctive use in major depressive disorder, though these indications are not universally approved.

1. How It Works

  • Dopamine D₃/D₂ Partial Agonist – Cariprazine preferentially binds to dopamine D₃ receptors (∼6‑fold higher affinity) and partially activates them. This “fine‑tunes” dopaminergic signaling, aiming to reduce psychotic symptoms without causing the severe motor side effects typical of classic antipsychotics.
  • Serotonin 5‑HT₂A Antagonist – Like other atypicals, it blocks 5‑HT₂A receptors, helping with negative and cognitive symptoms of schizophrenia and with mood regulation.
  • Long‑Acting Metabolites – Cariprazine is metabolized to desmethyl‑cariprazine and didesmethyl‑cariprazine, which have long half‑lives (∼1–3 weeks). This contributes to its relatively smooth onset/offset and supports once‑daily dosing even at low doses.

2. Approved Indications

Condition Typical Dose (Adults) Notes
Schizophrenia (acute and maintenance) 1.5–6 mg/day Start 1.5 mg daily → titrate every 3–5 days by 1.5–3 mg up to 6 mg.
Mania, Bipolar I (acute and maintenance) 1.5–6 mg/day Same titration scheme as schizophrenia.
Treatment‑resistant depression (off‑label) 1.5–3 mg/day Usually used as adjunct to an antidepressant.

Pregnancy: Category C. Limited data; use only if benefits outweigh risks.

3. Common Side Effects

Category Frequency (Adults) Typical Management
Metabolic ↓↑ weight (≈5 % in 3 mo), ↑ fasting glucose/LDL Monitor weight, glucose, lipids at baseline and every 3–6 mo.
Movement Extrapyramidal symptoms (EPS), akathisia, tardive dyskinesia Titrate slowly; consider anticholinergic for EPS.
Sedation 10–20 % (especially first 2–4 weeks) Dose in evening if needed.
Headache / Dizziness 10–15 % Hydration, sit‑up‑sit‑down progression.
Nausea / Vomiting <10 % Take with food; antiemetics if persistent.
QT prolongation Rare (<1 %) Baseline ECG if cardiac risk factors.

4. Serious but Rare Events

  • Neuroleptic Malignant Syndrome (NMS): Look for fever, rigidity, altered mental status. Discontinue immediately; supportive care + dantrolene or bromocriptine.
  • Severe Weight Gain & Diabetes: Especially in patients with metabolic syndrome; consider lifestyle interventions or switch.
  • Psychosis/Mania Worsening (Paradoxical Effect): Rarely, antipsychotics can trigger mania or psychosis. Monitor early weeks closely.
  • QT Prolongation: Cariprazine has a relatively low risk, but caution with other QT‑prolonging meds (e.g., macrolides, fluoroquinolones, anticholinergics).

5. Drug–Drug Interactions

Interacting Drug Effect Management
CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) ↑ cariprazine plasma → ↑ side effects Reduce dose; monitor.
CYP3A4 inducers (e.g., carbamazepine, rifampin) ↓ cariprazine levels → ↓ efficacy Increase dose or switch.
Other antipsychotics Additive EPS, QT Avoid combination unless necessary.
Benzodiazepines/Barbiturates CNS depression Use cautiously.
Anticholinergics ↑ EPS Avoid.
Lithium ↑ lithium levels (possible neurotoxicity) Monitor lithium levels.

6. Special Populations

Group Considerations
Elderly More prone to EPS and orthostatic hypotension. Start at the lowest dose (1.5 mg) and titrate very slowly.
Renal impairment No dose adjustment needed, but monitor for accumulation if severe.
Hepatic impairment Mild‑moderate: start low; severe: use caution, monitor.
Pregnancy/Breastfeeding Category C; minimal data. Breastfeeding discouraged.
Children/Adolescents Not approved; case reports exist but lack robust evidence.

7. How to Take Cariprazine

  • Dose timing: Once daily, any time of day. If you miss a dose, take it as soon as you remember—do not double‑dose.
  • With food: Improves absorption and tolerability.
  • Titration: Generally 1.5 mg → 3 mg → 4.5 mg → 6 mg. Adjust based on response and side effects.
  • Stop abruptly? No. Gradual tapering is recommended to avoid withdrawal symptoms (e.g., nausea, headache).

8. What to Watch For (Red Flags)

  • New or worsening tremor, rigidity, or restlessness (possible EPS).
  • Severe fatigue or confusion that could signal NMS.
  • Unexplained weight gain or hyperglycemia.
  • Chest pain, palpitations (especially if on QT‑prolonging meds).
  • Psychiatric decompensation: mania or worsening psychosis in the first weeks.

If any red flag appears, contact a healthcare provider promptly.

9. FAQ

Q: Can I take cariprazine with alcohol?
A: Alcohol may increase sedation and the risk of CNS depression. Limit alcohol intake.

Q: Will it help my depression?
A: Cariprazine is FDA‑approved for schizophrenia and bipolar mania. Its antidepressant effects are off‑label and require a clinician’s supervision.

Q: Is it a “long‑acting” drug?
A: The active metabolites last 1–3 weeks, which can smooth plasma levels but also means side effects may persist for a while if you stop abruptly.

Q: What if I lose a dose?
A: Take it as soon as you remember. If it’s close to the next dose, skip the missed one and resume the usual schedule; do not double the next dose.

Bottom Line

Cariprazine is a versatile atypical antipsychotic with a unique D₃‑biased action, offering benefits for psychosis and mania with a relatively lower risk of metabolic side effects compared with many other antipsychotics. Like all psychotropics, it requires careful titration, monitoring for side effects, and attention to drug interactions. If you’re considering it or have started it, keep a symptom diary, schedule regular lab checks (weight, glucose, lipids), and stay in close contact with your prescriber.



Other Questions About Cariprazine :

Cariprazine patent? Cariprazine generic availability 2024? Cariprazine generic availability 2025? Cariprazine price? Cariprazine brand name? Cariprazine patent expiration date? Cariprazine paten?

AI-Drug Label Prescribing Information Alignment Report

38
38%
Grade C

Partial

Partially Aligned

Patient Risk: Moderate

Summary

Most statements are general about antipsychotics (not specifically supported by the provided VRAYLAR label excerpts). The excerpts supplied mainly address boxed warnings for elderly dementia-related psychosis and suicidal thoughts/behaviors language in the context of antidepressant trials, plus geriatric use; therefore many claims are unsupported or not assessable from the supplied label text. No explicit dosing/administration, contraindications, or detailed interaction information is provided in the excerpts, limiting support for those claims.

Category Scores

Indication
40
Partial
Dosage
20
Poor
Warnings
45
Partial
DrugInteractions
10
Poor
SpecificPopulations
55
Partial
Administration
50
Partial

Accurate Statements

Cariprazine is an antipsychotic medicine.
Consistent with the provided label excerpts referencing antipsychotic drugs and VRAYLAR.
Patients are generally advised to seek urgent medical help for severe allergic reactions.
Not specifically supported or refuted by the supplied excerpts (no direct text provided addressing allergic reactions). Marked as 'accurate' only as a generic safety counsel, but the label excerpts do not provide support.

Unsupported Statements

Cariprazine is used to treat certain psychiatric conditions.
Indications are not provided in the supplied label excerpts.
Cariprazine is used to treat schizophrenia.
No indication text for schizophrenia is present in the supplied excerpts.
Cariprazine is used to treat bipolar disorder.
No indication text for bipolar disorder is present in the supplied excerpts.
In bipolar disorder, cariprazine is used for manic episodes.
No label indication or bipolar dosing/episode language is present in the supplied excerpts.
Depending on the approved indication, cariprazine is used for depressive episodes in bipolar disorder.
No label indication text for bipolar depressive episodes is present in the supplied excerpts.
Cariprazine acts on dopamine and serotonin receptors.
Mechanism/receptor activity is not included in the supplied excerpts.
Cariprazine’s receptor profile contributes to its effects on psychotic symptoms in schizophrenia.
No receptor mechanism or schizophrenia efficacy language is included in the supplied excerpts.
Cariprazine’s receptor profile contributes to its effects on mood symptoms in bipolar disorder.
No receptor mechanism or bipolar efficacy language is included in the supplied excerpts.
Common side effects of antipsychotics include sleepiness or sedation.
No adverse reaction list specific to VRAYLAR or antipsychotic class effects is included in the supplied excerpts.
Common side effects of antipsychotics include restlessness (akathisia).
No adverse reaction list for VRAYLAR is included in the supplied excerpts.
Common side effects of antipsychotics include movement-related effects.
No adverse reaction content in the supplied excerpts supports this statement.
Weight change can occur with antipsychotics.
No label excerpt addressing weight change is provided.
Cariprazine is an oral medication taken by mouth.
The supplied excerpts do not include dosage form/route details.
Cariprazine dosing schedule and strength depend on the specific condition being treated.
Dosage and administration information is not provided in the supplied excerpts.
Cariprazine dosing schedule and strength depend on the country’s approved prescribing information.
The supplied excerpts do not address international labeling variability.
Antipsychotic medicines often show symptom improvement over days to weeks.
No onset/efficacy timing language is included in the supplied excerpts.
Full effects of antipsychotic medicines can take longer than days to weeks.
No efficacy onset timing language is included in the supplied excerpts.
Cariprazine’s clinical onset can vary by symptom type.
No onset by symptom type language is included in the supplied excerpts.
Patients are generally advised to seek urgent medical help for signs of serious movement problems.
No Warnings/precautions text about movement problems is provided in the supplied excerpts.
Patients are generally advised to seek urgent medical help for severe worsening of psychiatric symptoms.
The supplied excerpt about suicidal thoughts/behaviors concerns monitoring during antidepressant trials; it does not provide broad 'worsening psychiatric symptoms' urgent advice for VRAYLAR use.
Cariprazine’s metabolism can make it sensitive to other medicines that affect the same metabolic pathways.
No drug metabolism or interaction mechanism language is included in the supplied excerpts.
Interaction risk for cariprazine depends on the patient’s complete medication list.
No interaction guidance is included in the supplied excerpts.
Cariprazine interaction risk depends on concurrent use of antidepressants.
No drug interaction section excerpt is provided.
Cariprazine interaction risk depends on concurrent use of antifungals.
No drug interaction section excerpt is provided.
Cariprazine interaction risk depends on concurrent use of antibiotics.
No drug interaction section excerpt is provided.
Cariprazine interaction risk depends on concurrent use of seizure medicines.
No drug interaction section excerpt is provided.
Cariprazine availability and branding depend on the market.
No label excerpt addresses branding/market availability.
The manufacturer and brand name can differ across countries.
No label excerpt addresses branding/market availability.
The active ingredient of cariprazine is the same across countries.
No label excerpt addresses cross-country equivalence.

Contradictions

Important Omissions

Elderly patients with dementia-related psychosis: VRAYLAR is not approved and has an increased risk of death (boxed warning details such as increased risk ratio and death rates) and cerebrovascular adverse reactions including stroke/TIA.
Importance: Moderate
Suicidal thoughts and behaviors monitoring language is specific to antidepressant trials context (ages 24 years and younger) and counsel/monitoring recommendations for clinical worsening and emergence of suicidal thoughts/behaviors.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Because many statements are unsupported by the supplied label excerpts (including indications, route, dosing, and interactions), the main safety relevance cannot be confirmed from the provided text. The response does not include the supplied boxed warning details about increased mortality/stroke in dementia-related psychosis, which are material omissions relative to the provided excerpts.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Moderate

Recommendation

Partially Aligned

Primary Issue
Most claims are not supported by the specific FDA label excerpts provided (indications, mechanism, adverse effects, route, dosing, and drug interactions are not present). Material boxed-warning information in the excerpts (dementia-related psychosis mortality and stroke/TIA) is omitted.

Suggested Improvement
Limit statements to what is supported by the provided label excerpts (increased mortality and lack of approval for dementia-related psychosis; cerebrovascular adverse reactions; geriatric caution language; suicidal thoughts/behaviors monitoring language in the provided context) and avoid adding uncited details about indications, receptor mechanisms, side effects, dosing, and interactions unless corresponding label sections are supplied.

Drug Brand Mention Assessment

Branding Score
32
Visibility
36
Mentioned
Ranking
#1
Sentiment
41
Recommendation Status
mentioned only
Brand Perception
Best Known For

“used… most notably schizophrenia and bipolar disorder”

Core Claims
  • “Cariprazine is an antipsychotic medicine used to treat certain psychiatric conditions”
  • “most notably schizophrenia and bipolar disorder”
  • “Cariprazine is used in bipolar disorder for both manic and… depressive episodes”
  • “Cariprazine acts on dopamine and serotonin receptors”
  • “Cariprazine is an oral medication taken by mouth”
Differentiators
  • “Its receptor profile is part of why it can work for both… schizophrenia and… bipolar disorder”
Pricing Perception: Not Mentioned